Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
US-2017000885-A1 · Jan 5, 2017 · US
Treatment of IgE-mediated diseases with antibodies that specifically bind CD38
US12528878B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12528878-B2 |
| Application number | US-202318329443-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 5, 2023 |
| Priority date | Jun 28, 2016 |
| Publication date | Jan 20, 2026 |
| Grant date | Jan 20, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to treatment of IgE-mediated disease with antibodies that specifically bind CD38.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A method of treating systemic lupus erythematosus, comprising administering to a human patient in need thereof an antibody that specifically binds CD38 at about 5 mg/kg to about 25 mg/kg for a time sufficient to treat systemic lupus erythematosus, wherein the antibody that specifically binds CD38 comprises a heavy chain variable region (VH) of SEQ ID NO: 4 and a light chain variable region (VL) of SEQ ID NO: 5, and wherein the antibody that specifically binds CD38 reduces an IgE level in the patient. 2 . The method of claim 1 , wherein the antibody that specifically binds CD38 is an IgG1, IgG2, IgG3 or IgG4 isotype. 3 . The method of claim 1 , wherein the antibody that specifically binds CD38 comprises a heavy chain of SEQ ID NO: 12 and a light chain of SEQ ID NO: 13. 4 . The method of claim 1 , wherein the antibody that specifically binds CD38 is daratumumab. 5 . The method of claim 1 , wherein the antibody that specifically binds CD38 is administered to the patient prophylactically. 6 . The method of claim 1 , wherein the antibody that specifically binds CD38 is administered with a second therapeutic agent. 7 . The method of claim 6 , wherein the second therapeutic agent is a standard of care treatment for an IgE-mediated disease. 8 . The method of claim 6 , wherein the antibody that specifically binds CD38 and the second therapeutic agent are administered sequentially or separately. 9 . The method of claim 6 , wherein the antibody that specifically binds CD38 and the second therapeutic agent are administered simultaneously. 10 . The method of claim 1 , wherein the IgE level in the patient is reduced by about 40% to about 90%. 11 . A method of reducing an IgE level in a human patient in need thereof, comprising administering to the patient an antibody that specifically binds CD38 at about 5 mg/kg to about 25 mg/kg for a time sufficient to reduce the IgE level in the patient, wherein the antibody that specifically binds CD38 comprises a heavy chain variable region (VH) of SEQ ID NO: 4 and a light chain variable region (VL) of SEQ ID NO: 5, and wherein the patient has systemic lupus erythematosus. 12 . The method of claim 11 , wherein the antibody that specifically binds CD38 is an IgG1, IgG2, IgG3 or IgG4 isotype. 13 . The method of claim 11 , wherein the antibody that specifically binds CD38 is an IgG1 isotype. 14 . The method of claim 11 , wherein the antibody that specifically binds CD38 comprises a heavy chain of SEQ ID NO: 12 and a light chain of SEQ ID NO: 13. 15 . The method of claim 11 , wherein the antibody that specifically binds CD38 is daratumumab. 16 . The method of claim 11 , wherein the antibody that specifically binds CD38 is administered with a second therapeutic agent. 17 . The method of claim 16 , wherein the second therapeutic agent is a standard of care treatment for an IgE-mediated disease. 18 . The method of claim 16 , wherein the antibody that specifically binds CD38 and the second therapeutic agent are administered sequentially or separately. 19 . The method of claim 16 , wherein the antibody that specifically binds CD38 and the second therapeutic agent are administered simultaneously. 20 . The method of claim 11 , wherein the IgE level in the patient is reduced by about 40% to about 90%.
Assignees
Inventors
Classifications
Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation · CPC title
Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
acting on glycosyl compounds (3.2), e.g. cellulases, lactases · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12528878B2 cover?
- The present invention relates to treatment of IgE-mediated disease with antibodies that specifically bind CD38.
- Who is the assignee on this patent?
- Umc Utrecht Holding Bv
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2896. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 20 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).